TAMPER-EVIDENT PACKAGING FOR DERMATOLOGICAL OTCs URGED BY ASHP
This article was originally published in The Tan Sheet
TAMPER-EVIDENT PACKAGING FOR DERMATOLOGICAL OTCs URGED BY ASHP in March 18 comments on FDA's proposed rule on tamper-evident packaging requirements for OTCs published in the Jan. 18 Federal Register ("The Tan Sheet" Jan. 24, p. 1). While lending support to FDA's proposal to require that all two-piece, hard-shell caps sold over-the-counter be sealed, the American Society of Hospital Pharmacists recommended that FDA "reconsider its regulatory exclusion of other dosage forms from tamper-evident packaging requirements, including dermatologicals."
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC